Expression of PAWR predicts prognosis of ovarian cancer
- PDF / 1,979,106 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 51 Downloads / 188 Views
Cancer Cell International Open Access
PRIMARY RESEARCH
Expression of PAWR predicts prognosis of ovarian cancer Jiahong Tan1,2, Kangjia Tao1,2, Xu Zheng1,2, Dan Liu1,2, Ding Ma1,2 and Qinglei Gao1,2*
Abstract Background: Ovarian cancer greatly threatens the general health of women worldwide. Implementation of predictive prognostic biomarkers aids in ovarian cancer management. Methods: Using online databases, the general expression profile, target-disease associations, and interaction network of PAWR were explored. To identify the role of PAWR in ovarian cancer, gene correlation analysis, survival analysis, and combined analysis of drug responsiveness and PAWR expression were performed. The predictive prognostic value of PAWR was further validated in clinical samples. Results: PAWR was widely expressed in normal and cancer tissues, with decreased expression in ovarian cancer tissues compared with normal tissues. PAWR was associated with various cancers including ovarian cancer. PAWR formed a regulatory network with a group of proteins and correlated with several genes, which were both implicated in ovarian cancer and drug responsiveness. High PAWR expression denoted better survival in ovarian cancer patients (OS: HR = 0.84, P = 0.0077; PFS, HR = 0.86, P = 0.049). Expression of PAWR could predict platinum responsiveness in ovarian cancer and there was a positive correlation between PAWR gene effect and paclitaxel sensitivity. In 12 paired clinical samples, the cancerous tissues exhibited significantly lower PAWR expression than matched normal fallopian tubes. The predictive prognostic value of PAWR was maintained in a cohort of 50 ovarian cancer patients. Conclusions: High PAWR expression indicated better survival and higher drug responsiveness in ovarian cancer patients. PAWR could be exploited as a predictive prognostic biomarker in ovarian cancer. Keywords: Drug responsiveness, Ovarian cancer, PAWR, Survival Background Ovarian cancer ranks seventh the most common cancer, causing 152,000 deaths annually worldwide (4.3% of all cancer deaths), and the 5-year survival rate for ovarian cancer has remained unchanged for decades [1]. Highgrade serous ovarian cancer is the most common histological subtype, which is thought to originate from the fallopian tubes and is characterized by nearly universal *Correspondence: [email protected] 1 Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430030, People’s Republic of China Full list of author information is available at the end of the article
TP53 gene abnormalities [1]. The introductions of platinum in 1976 and paclitaxel in 1993 have greatly improved the outcomes of ovarian cancer patients [1–3]. Currently, combination regimens containing carboplatin and paclitaxel are the global standard of care [4]. A response rate of approximately 80% has been noted in initial chemotherapy [1]. However, the majority of patients develop
Data Loading...
